For this, we selected the A549 human lung adenocarcinoma cell line for transfection since this line overexpresses an oncogenic KRas mutant (G12S) but expresses no endogenous RASSF5, thus allowing us to introduce our engineered mutants on a null background. This evidence concerns the gene KRAS and lung adenocarcinoma.